Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzyme Engineering. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN118126972A reveals acid-resistant carbonyl reductase mutant for efficient (S)-NBHP synthesis, offering significant cost reduction and supply chain reliability.
Patent CN118126972A reveals enhanced enzyme mutant for (S)-NBHP production offering superior acid resistance and reduced processing costs for pharmaceutical supply chains.
Patent CN119823958B reveals high-yield enzyme route for Clopidogrel intermediate offering cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN116731988B reveals high-purity pharmaceutical intermediates synthesis via engineered ketoreductase, ensuring supply chain reliability and cost reduction.
Patent CN102174422B reveals high-activity lipase for chiral resolution. Offers solvent stability and cost reduction in biocatalysis manufacturing for pharma intermediates.
Novel aminotransferase mutant enables 99% ee sitagliptin intermediate. Robust DMSO tolerance ensures cost reduction in pharma manufacturing.
Patent CN119614528B reveals enhanced hydroxysteroid dehydrogenase mutants for steroid synthesis, offering improved stability and cost reduction in pharmaceutical manufacturing.
Patent CN115433721B details a carbonyl reductase mutant for BHBM synthesis, offering water-based media and superior thermal stability for cost-effective pharma manufacturing.
Patent CN115786313A reveals a novel nitrilase mutant boosting 2-chloronicotinic acid yield by 23.2 times, offering a green alternative for pharma and agrochemical intermediates.
Patent CN104630241A enables high-purity statin intermediate production with reduced waste and enhanced supply chain reliability for global pharmaceutical manufacturing partners seeking cost efficiency.
Patent CN111051506A discloses engineered PGA variants for efficient insulin dimer deprotection. Discover cost reduction in pharmaceutical intermediates manufacturing and supply chain advantages.
Novel carbonyl reductase mutants enhance chiral alcohol synthesis yield and stability for pharmaceutical manufacturing supply chains ensuring reliable high-purity intermediate sourcing.
Patent CN114277023B details a biocatalytic route for nicotinamide using recombinant enzymes and ion exchange resin for superior purity and cost efficiency.
Patent CN107384885B reveals enzymatic synthesis of chiral amines. Achieve cost reduction in API manufacturing with high conversion and optical purity.
Patent CN112680425B reveals a novel alcohol dehydrogenase mutant for producing high-purity (S)-CHBE. This biocatalytic route offers significant cost reduction and supply chain reliability for statin manufacturing.
Patent CN108893455A details a transaminase mutant for L-glufosinate-ammonium production. Achieves 98% yield and 99% ee. Ideal for agrochemical intermediate supply chains seeking cost reduction.
Patent CN105821090A details a novel NAD(H)-dependent StDapdh mutant for D-alanine synthesis, offering enhanced stability and cost-effective biocatalytic manufacturing solutions.
Patent CN104894148A details a high-efficiency omega-transaminase mutant for chiral amine synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN113322219A reveals high-efficiency biocatalytic route for curcumin glucosides offering enhanced solubility and scalable production for pharmaceutical and food industries
Patent CN119709674A reveals efficient BBE mutant for (S)-Scolerine. Enables cost reduction and scalable supply for pharmaceutical intermediate manufacturing.